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Child-Friendly version of EQ-5D will be discussed to realize the
ﬁnal version of the questionnaire.
PIH15
DEVELOPMENT OF AN ICIQ NOCTURNAL ENURESIS 
QOL QUESTIONNAIRE
Holm-Larsen T1, Hansson M2, Riis A2, Gennaro M3, Hagstrom S4,
Nørgaard JP5
1University of Pharmaceutical Sciences, Copenhagen, Denmark,
2Ferring Pharmaceuticals A/S, Copenhagen, Denmark, 3Bambino Gesù
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OBJECTIVES: There is a lack of a validated QoL questionnaire
assessing the psychological burden and treatment beneﬁts of bed-
wetting as evaluated by the child. This abstract reports the results
of the initial validation tests for such a questionnaire. It is being
developed in accordance with the validation standards of the
ICIQ. METHODS: A literature review was conducted and led
to quantitative interviews with 28 children suffering from Noc-
turnal Enuresis and 28 pairs of parents. Consequently a ques-
tionnaire including 20 questions was developed and tested in a
multinational Randomised Clinical Trial completed by 196 chil-
dren and 196 parents in antidiuretic treatment before and during
the trial. RESULTS: Based on review and interviews, a list of
issues was identiﬁed: Social isolation, emotional distress, low
self-esteem, problems in parent-child relation, delayed indepen-
dence and fear of being teased at school and home. Two or more
questions were developed for each of the six issues to add room
for elimination of poorly performing questions. The RCT data
indicated promising cluster effect, i.e. the well treated children
showed a high QoL, and the questions seemed test-retest con-
sistent. Some questions yield a high level of missing answers.
CONCLUSION: The tests led to reformulation of the questions
yielding missing answers and the questionnaire is now ready for
the coming validation, including sensitivity analysis and item
reduction. We are convinced that future research in Nocturnal
Enuresis will proﬁt from the ﬁnal questionnaire.
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TREATMENT DURATION FOR ATROPHIC VAGINITIS:
CLINICAL TRIALS VERSUS “THE REAL WORLD”
Balu S1, Lee WC2, Joshi AV3, Cobden D3, Pashos CL1
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OBJECTIVE: Duration of vaginal estrogen therapy (VET) may
vary. This study sought to compare and contrast treatment dura-
tion of women prescribed vaginal tablets (VT) or vaginal creams
(VC) in clinical trials with that in clinical practice. METHODS:
Adults initiating VET between January and June, 2004 in 57
managed care plans (PharMetrics database) in the United States
were identiﬁed and followed for up to 10 months to examine
their treatment duration. A Kaplan-Meier analysis was per-
formed to obtain average and median time to discontinuation
for individuals treated with VT or VC. A weighted average of
treatment duration was calculated for a total of seven clinical
trials identiﬁed in the literature. These results were stratiﬁed by
study inclusion criteria. Differences in average treatment duara-
tion were statistically tested using t-tests. RESULTS: Of 5599
patients undergoing VET (mean age = 54 ± 9.1 years), 4355
(77.8%) received VC and 1244 (22.2%) received VT. Patients
prescribed VT had a signiﬁcantly longer average (median) treat-
ment compared to patients prescribed VC [(198.5 ± 82.4 days
(221 days) vs. 177.1 ± 86.7 days (190 days)); p < 0.01)]. This
duration in clinical practice was signiﬁcantly longer than that in
seven clinical trials [165 days (240 days for three trials of both
VC and VT; 90 days for two VT-only studies; and 69 days for
two VC-only studies)]. CONCLUSIONS: Duration of VET was
longer in a real-world clinical practice setting than in clinical
trials. Moreover, subjects treated with VT exhibited signiﬁcantly
longer treatment duration than subjects treated with VC. Possi-
ble factors explaining longer duration with VT include ease of
use, reduced messiness, accurate dosing resulting in improved
effectiveness and fewer adverse events, and consequently
improved quality of life. Future studies should prospectively
examine factors associated with these differences.
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ASSESSING PSYCHOLOGICAL BURDEN AND TREATMENT
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OBJECTIVES: Nocturnal enuresis (NE) can pose signiﬁcant psy-
chological burden on children’s self-esteem and quality of life
(QoL). Therefore, patient-reported outcome (PRO) measure-
ment is essential to fully understand the burden posed by NE
and the beneﬁts of treating this condition. To our knowledge, it
has not been investigated which instruments should be used to
assess the psychological burden of NE. The aim of this study was
to identify and evaluate PRO instruments used in children with
NE. METHODS: A literature search of Medline and other data-
bases was conducted to identify publications from 1995–2006
which contained PRO instruments used in children with NE.
RESULTS: 40 studies and 32 PRO instruments were identiﬁed.
Instruments were evaluated based on psychometric properties
and responsiveness to change. Some studies used several PRO
instruments. The Child Behavior Checklist was the most 
commonly used instrument (8/40 studies, 20%). Measures of
self-esteem were used in 11/40 studies (28%). No generic QoL
measures were used in these trials. No disease-speciﬁc PRO
instruments were found to be fully validated in the NE. popula-
tion. Currently, a new disease-speciﬁc QoL questionnaire is in
development for NE. CONCLUSIONS: The results of this study
highlight the lack of patient-reported disease-speciﬁc PRO mea-
sures to assess the burden and treatment beneﬁts of NE. A new
disease-speciﬁc instrument may be able to ﬁll this gap.
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OBJECTIVES: To compare Finnish patients with erectile dys-
function (ED) and men from the Finnish general population in
measures of self-reported Health-Related QOL (HRQoL) and
satisfaction with life, and to investigate whether switching
patients from current oral ED medication to tadalaﬁl impacts
these measures. METHODS: A total of 202 Finnish men over
18 years successfully treated with oral ED prescription medica-
tion (tadalaﬁl excluded) voluntarily entered this multicenter,
open-label, one-arm, 3-month study. Upon enrollment, patients
discontinued their previous therapy and were started on tadalaﬁl
10 or 20 mg (dose determined by investigator) on demand.
Outcome was measured using the 15D and Life Satisfaction-11
(LiSat-11) checklists. 15D is a generic, comprehensive, 15-
dimensional, standardized, self-administered measure of HRQoL
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used as both a proﬁle and single score measure. LiSat-11 is a
generic validated checklist for self-perceived satisfaction with
life. A Finnish, age-matched male population cohort was used
for comparison. RESULTS: A total of 194 patients provided data
for analysis at baseline and outcome at 3 months. The changes
observed (baseline to endpoint) were as follows: average usage
of ED tablets per four weeks increased from 4.7 to 9.7, inter-
course attempts from 6.4 to 10.6, and the success rate of inter-
courses from 79% to 92%. At baseline, the 15D score was higher
for the study patients than for the comparator population (0.924
vs. 0.902). Nevertheless, signiﬁcant improvement (baseline to
endpoint) was reported on the 15D dimensions of mobility,
depression, distress (all p < 0.01), and sexual activity (p < 0.001);
and life in general (p < 0.05), leisure (p < 0.01), sexual life, family
life, and partnership relation (all p < 0.001) domains of LiSat-
11. CONCLUSIONS: When patients switched from other oral
ED medication to tadalaﬁl, improvement was seen in 3 of 15
dimensions of 15D and in 5 out of 11 domains of LiSat-11,
including the closeness items: sexual life, partnership relation,
and family life.
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OBJECTIVE: To estimate the health state utility of differing
severities of gastro-enteritis associated with rotavirus infection in
children under ﬁve. METHODS: Health state descriptions were
developed based on the major symptoms of gastro-enteritis infec-
tion. Health states for children who could be treated at home and
those requiring hospitalisation were presented to GPs (N = 25),
and for hospitalised cases, health states for children with two
levels of dehydration were presented to paediatricians (N = 25).
Both GPs and paediatricians were asked to score these health
states using the EQ-5D questionnaire for children in two age
bands (< 18 months, 1.5–5 years). Scores were modiﬁed to take
into account the limited capacity for mobility and self-care among
children in this age range. Utility estimates were calculated from
these scores using standard methodology. RESULTS: From GP
scores subjects requiring or not hospitalisation have a mean utility
value (95% CI) of 0.425 (95 CI: 0.330; 0.520) and 0.781 (95 CI:
0.678; 0.884) in children <18 months, and 0.200 (95 CI: 0.049;
0.352) and 0.688 (95 CI: 0.553; 0.824) in children 1.5 yrs–5 yrs
respectively. From paediatrician scores, mean utility values for
hospitalised cases with 3–8% and ≥9% dehydration were 0.595
(95 CI: 0.528; 0.662) and 0.256 (95 CI: 0.157; 0.354) in chil-
dren <18 months, and 0.634 (95 CI: 0.549; 0.718) and 0.077 (95
CI: −0.057; 0.210) in children 1.5 yrs–5 yrs respectively. In each
case, conﬁdence intervals between severe and less severe health
states did not overlap. CONCLUSION: Gastroenteritis associ-
ated with rotavirus has a signiﬁcant impact on the health related
quality of life in children under ﬁve. This study provides useful
estimates of health state utilities for economic evaluation of inter-
ventions to prevent rotavirus infection.
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CONJOINT-ANALYSIS QALYS FOR ACUTE CONDITIONS
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OBJECTIVE: Demonstrate using conjoint analysis to obtain gen-
eralized, nonlinear, time-tradeoff estimates of quality-adjusted
life-years (QALYs) for clinically relevant durations and severities
of acute, non-fatal conditions such as vasomotor symptoms.
METHODS: A self-administered, web-enabled, graded-pairs
conjoint-analysis survey elicited women’s preferences for the
treatment of vasomotor symptoms. The included treatment
attributes are frequency and severity of vasomotor symptoms
(daytime hot ﬂashes and nighttime sweats) and duration of these
symptoms. Participants also considered vasomotor-symptom,
treatment-related side effects. Observed tradeoffs between
symptom duration and symptom relief were used to calculate
generalized conjoint time equivalents for speciﬁed health states
without ﬁrst calculating utilities anchored at 0 and 1. RESULTS:
A total of 523 women with a mean age of 52 years completed
the survey. For these women, improvement from severe (severe
>6 hot ﬂushes a day and >3 sweats a night) to moderate (mod-
erate 3–6 hot ﬂushes a day and 1–3 sweats a night) vasomotor
symptoms over a 7-year treatment period is equivalent to 3.7
years of normal health, while improvement from moderate to
mild (mild 1–2 hot ﬂushes a day and no night sweats) symptoms
is equivalent to 4.4 years of normal health. QALY beneﬁts of
symptom relief are larger for younger women (<= 2) than for
older women (>52). For example, an improvement from moder-
ate to mild is equivalent to 3.3 years of normal health for
younger women, where it is to 6.8 years of normal health for
older women. CONCLUSIONS: Conjoint analysis is a feasible
method for estimating QALYs directly for acute health states.
This approach avoids ad hoc approaches such as the chaining
method. Its advantages over standard-gamble and time-tradeoff
methods include avoiding clinically irrelevant tradeoffs involv-
ing death or life expectancy, avoiding restrictive assumptions
such as linear time preferences, and eliciting preferences in the
realistic context of both efﬁcacy and side-effect risks.
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Erectile dysfunction (ED) is deﬁned as the persistent or recurring
incapacity to achieve or maintain sufﬁcient rigidity of the penis
to be able to have satisfactory sexual intercourse. OBJECTIVE:
To determine the clinical response to treatment (patient satis-
faction, onset of action and reproducibility of the effect) in
patients with ED, with or without other concomitant diseases.
METHODS: A retrospective, epidemiological study was con-
ducted in which we collected demographic data, medical and
sexual history, concomitant medication, diagnostic and thera-
peutic procedures applied to ED and the clinical response to the
prescribed treatment in male patients over 18 years of age who
had visited their doctor in the 3 months prior to the start of the
study. RESULTS: data was collected from 5281 patients. The
most prevalent associated disorders were cardiovascular
(28.6%), endocrine (23.7%) and genitourinary (15.4%). A total
of 77.1% of the patients with concomitant disorders indicated
they were satisﬁed with the erection obtained (sufﬁcient for inter-
course) (90.9% of the patients without other associated disor-
ders; p < 0.0001). A totalof he patients with concomitant
diseases referred they were satisﬁed with the onset of action of
the treatment (91.1% without other associated disorders; p <
0.0001). 75.8% of the patients with concomitant diseases were
conﬁdent to obtain and maintain a sufﬁcient erection at each new
attempt (90.0% without other associated disorders; p < 0.0001).
Clinical response was better in patients with cardiovascular or
endocrine conditions vs. genitourinary disorders (p < 0.03; p <
0.04). The mean prescribed dose was 15.9 mg (SD 5.2) of var-
denaﬁl, 18.6 mg (SD 6.9) of tadalaﬁl and 60.6 mg (SD 23.7) of
